A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Phase 1
18+
7 sites in NJ, NY
What this study is about
This Phase 1 study is testing Gemcitabine in people with diffuse pleural mesothelioma.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells), Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), oxaliplatin
injection (Injection), infusion
Secondary: Overall Response Rate (ORR), Progression-free survival (PFS)
Oncology